These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 1306523

  • 1. Prolactinomas and resistance to dopamine agonists.
    Brue T, Pellegrini I, Priou A, Morange I, Jaquet P.
    Horm Res; 1992; 38(1-2):84-9. PubMed ID: 1306523
    [Abstract] [Full Text] [Related]

  • 2. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
    Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P.
    Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
    [Abstract] [Full Text] [Related]

  • 3. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
    Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
    [Abstract] [Full Text] [Related]

  • 4. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK, Vance ML, Boulos PT, Laws ER.
    Pituitary; 2005 Mar; 8(1):53-60. PubMed ID: 16411069
    [Abstract] [Full Text] [Related]

  • 5. Resistance to bromocriptine in prolactinomas.
    Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A.
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [Abstract] [Full Text] [Related]

  • 6. CV 205-502 treatment of macroprolactinomas.
    Crottaz B, Uske A, Reymond MJ, Rey F, Siegel RA, Brownell J, Gomez F.
    J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
    [Abstract] [Full Text] [Related]

  • 7. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
    Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM.
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ, Brownell J, Lamberts SW.
    J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
    [Abstract] [Full Text] [Related]

  • 9. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G.
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [Abstract] [Full Text] [Related]

  • 10. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B, Nesher Y, Barziliai S.
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of prolactinoma with a new dopamine agonist].
    Svoboda T, Luger A, Knosp E, Geyer G.
    Dtsch Med Wochenschr; 1991 Aug 16; 116(33):1224-7. PubMed ID: 1678695
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
    Rohmer V, Freneau E, Morange I, Simonetta C.
    Ann Endocrinol (Paris); 2000 Nov 16; 61(5):411-7. PubMed ID: 11084391
    [Abstract] [Full Text] [Related]

  • 13. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J.
    Acta Neurochir (Wien); 2005 Jul 16; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [Abstract] [Full Text] [Related]

  • 14. Combined treatment of invasive giant prolactinomas.
    Yu C, Wu Z, Gong J.
    Pituitary; 2005 Jul 16; 8(1):61-5. PubMed ID: 16411070
    [Abstract] [Full Text] [Related]

  • 15. Management of resistant prolactinomas.
    Olafsdottir A, Schlechte J.
    Nat Clin Pract Endocrinol Metab; 2006 Oct 16; 2(10):552-61. PubMed ID: 17024154
    [Abstract] [Full Text] [Related]

  • 16. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment.
    Saeki N, Nakamura M, Sunami K, Yamaura A.
    Endocr J; 1998 Aug 16; 45(4):529-37. PubMed ID: 9881903
    [Abstract] [Full Text] [Related]

  • 17. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D, Lombardi G.
    Horm Res; 1995 Aug 16; 44(5):222-8. PubMed ID: 8582715
    [Abstract] [Full Text] [Related]

  • 18. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB, Su ZP, Wu JS, Zheng WM, Zhuge QC, Zhong M.
    Pituitary; 2008 Aug 16; 11(1):63-70. PubMed ID: 17917811
    [Abstract] [Full Text] [Related]

  • 19. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
    Höfle G, Gasser R, Mohsenipour I, Finkenstedt G.
    Exp Clin Endocrinol Diabetes; 1998 Aug 16; 106(3):211-6. PubMed ID: 9710362
    [Abstract] [Full Text] [Related]

  • 20. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, Christ E.
    Endocrine; 2017 Jan 16; 55(1):223-230. PubMed ID: 27688009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.